These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 1997518

  • 1. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
    Lamberts SW, Quik RF.
    J Clin Endocrinol Metab; 1991 Mar; 72(3):635-41. PubMed ID: 1997518
    [Abstract] [Full Text] [Related]

  • 2. Control of hyperprolactinemia with pergolide.
    Mattox JH, Bernstein J, Buckman MT.
    Int J Fertil; 1986 Mar; 30(4):39-43. PubMed ID: 2890594
    [Abstract] [Full Text] [Related]

  • 3. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia.
    Kletzky OA, Borenstein R, Mileikowsky GN.
    Am J Obstet Gynecol; 1986 Feb; 154(2):431-5. PubMed ID: 3080892
    [Abstract] [Full Text] [Related]

  • 4. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of women with amenorrhea-galactorrhea treated with bromocriptine.
    Tartagni M, Nicastri PL, Diaferia A, Di Gesù I, Loizzi P.
    Clin Exp Obstet Gynecol; 1995 Jul; 22(4):301-6. PubMed ID: 8777784
    [Abstract] [Full Text] [Related]

  • 6. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs.
    Berezin M, Avidan D, Baron E.
    Isr J Med Sci; 1991 Jul; 27(7):375-9. PubMed ID: 2071373
    [Abstract] [Full Text] [Related]

  • 7. Dopamine agonists for reducing depression associated with hyperprolactinemia.
    Mattox JH, Buckman MT, Bernstein J, Pathak D, Kellner R.
    J Reprod Med; 1986 Aug; 31(8):694-8. PubMed ID: 3772890
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
    Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, Giordano G.
    J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B, Colao A, Caruso E, Sarnacchiaro F, Briganti F, Lancranjan I, Lombardi G, Schettini G.
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
    Morán C, Tena G, Fonseca ME, Ochoa R, Bermúdez JA, Zárate A.
    Arch Med Res; 1994 Dec; 25(1):1-3. PubMed ID: 8019107
    [Abstract] [Full Text] [Related]

  • 16. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
    Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF.
    N Engl J Med; 1994 Oct 06; 331(14):904-9. PubMed ID: 7915824
    [Abstract] [Full Text] [Related]

  • 17. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 2001 Nov 06; 86(11):5256-61. PubMed ID: 11701688
    [Abstract] [Full Text] [Related]

  • 18. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
    Factor SA, Sanchez-Ramos JR, Weiner WJ.
    J Neurol Neurosurg Psychiatry; 1988 Apr 06; 51(4):529-33. PubMed ID: 3288717
    [Abstract] [Full Text] [Related]

  • 19. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
    Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C.
    Gynecol Endocrinol; 1994 Sep 06; 8(3):175-81. PubMed ID: 7847102
    [Abstract] [Full Text] [Related]

  • 20. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
    Ferrari C, Mattei A, Melis GB, Paracchi A, Muratori M, Faglia G, Sghedoni D, Crosignani PG.
    J Clin Endocrinol Metab; 1989 Jun 06; 68(6):1201-6. PubMed ID: 2656736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.